90922-26-2

Upstream product

• 67-56-1 methanol 
• 122-85-0 para-acetamidobenzaldehyde 
• 1269834-09-4 C₁₁H₁₃NO₄ 
• 177478-52-3 4-acetamido-3-methoxybenzyl alcohol 
• 38512-82-2 3-methoxy-4-nitrotoluene 
• 90151-40-9 4-amino-3-methoxybenzaldehyde 
• 108-24-7 acetic anhydride 
• 41608-64-4 methyl 3-methoxy-4-aminobenzoate 

Downstream Products

• 93136-41-5 3-<4-Acetamino-3-methoxy-phenyl>-propionsaeure 
• 92288-42-1 3-<3-Methoxy-4-cyan-phenyl>-propionsaeure 
• 91819-02-2 3-<4-Amino-3-methoxy-phenyl>-propionsaeure 
• 73928-02-6 3-methoxy-trans-stilben-4-ylamine 
• 177478-56-7 4-Acetamido-3-methoxycinnamic acid 
• 88612-83-3 4-acetylamino-3-methoxy-cinnamic acid 

Relevant academic research and scientific papers

Diverse ortho-C(sp2)-H functionalization of benzaldehydes using transient directing groups

Pd-catalyzed C-H functionalizations promoted by transient directing groups remain largely limited to C-H arylation only. Herein, we report a diverse set of ortho-C(sp2)-H functionalizations of benzaldehyde substrates using the transient directing group strategy. Without installing any auxiliary directing group, Pd(II)-catalyzed C-H arylation, chlorination, bromination, and Ir(III)-catalyzed amidation, could be achieved on benzaldehyde substrates. The transient directing groups formed in situ via imine linkage can override other coordinating functional groups capable of directing C-H activation or catalyst poisoning, significantly expanding the scope for metal-catalyzed C-H functionalization of benzaldehydes. The utility of this approach is demonstrated through multiple applications, including late-stage diversification of a drug analogue.

Synthesis and preliminary evaluation of curcumin analogues as cytotoxic agents

A series of curcumin analogues with different substituents at the 4-position of the phenyl group were synthesized and screened for in vitro cytotoxicity against a panel of human cancer cell lines. Several novel curcumin analogues, especially 32 and 34, exhibited selective and potent cytotoxic activity against human epidermoid carcinoma cell line A-431 and human glioblastoma cell line U-251, implying their specific potential in the chemoprevention and chemotherapy of skin cancer and glioma. The preliminary SAR information extracted from the results suggested that introduction of appropriate substituents to the 4′-positions could be a promising approach for the development of new cytotoxic curcumin analogues with special selectivity for A-431 and U-251 cell lines.

Heterocyclic compounds as bradykinin antagonists

This invention relates to a compound of the formula: wherein A1is lower alkylene, R1is substituted quinolyl, etc., R2is hydrogen, halogen or lower alkyl, R3is halogen or lower alkyl, and R4is a group

Benzimidazole compounds as bradykinin antagonists

PCT No. PCT/JP95/01478 Sec. 371 Date Feb. 3, 1997 Sec. 102(e) Date Feb. 3, 1997 PCT Filed Jul. 25, 1995 PCT Pub. No. WO96/04251 PCT Pub. Date Feb. 15, 1996This invention relates to a heterocyclic compound of the formula: wherein a group of the formula: is a group of the formula: etc., X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

Heterocyclic compounds as bradykinin antagonists

This invention relates to a compound of formula (I) wherein A1 is lower alkylene, R1 is substituted quinolyl, etc., R2 is hydrogen, halogen or lower alkyl, R3 is halogen or lower alkyl, and R4 is a gr

Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists

This invention relates to a compound of the formula: STR1 wherein Z is a group of the formula: STR2 in which X1 is N or C--R1, X2 is N or C--R9, X3 is N or C--R2, R1 is lower alk